CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Mayne Pharma International Pty Ltd. v. Merck & Co., Inc.

1:15-cv-00438

📡 5G SEP • ETSI Declared

Overview

Case Number 1:15-cv-00438
Filing Date 2015-05-29
Status Terminated
Termination Date 2019-07-26
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand Plaintiff

Parties

Defendant

Merck Sharp & Dohme Corp. Operating Company

Represented By

3 Attorneys Listed

Stephen J. Kraftschik

Polsinelli PC

Tel: +1 (302) 252-0926
Fax: +1 (302) 252-0921

222 Delaware Avenue, Suite 1101, Wilmington, DE 19801

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Merck & Co., Inc. Operating Company

Represented By

5 Attorneys Listed

Stephen J. Kraftschik

Polsinelli PC

Tel: +1 (302) 252-0926
Fax: +1 (302) 252-0921

222 Delaware Avenue, Suite 1101, Wilmington, DE 19801

Robert W. Trenchard

Email: rtrenchard@gibsondunn.com

Jane M. Love

Email: jlove@gibsondunn.com

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

N.V. Organon NPE (Individual / Inventor)

Represented By

1 Attorneys Listed

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Plaintiff

Mayne Pharma International Pty Ltd. Operating Company

Represented By

7 Attorneys Listed

David M. Fry

JPMorgan Chase & Co.

Tel: +1 (302) 455-3374

JPMorgan Chase & Co., 4041 Ogletown Stanton Road

Seth I. Heller

UNDELIVERABLE EMAIL 7/23/2018

Ryan A. Cook

Email: rcook@mabr.com

Jeremy Lowe

Email: jlowe@axinn.com

Jason T. Murata

Email: jmurata@axinn.com

Eric P. Greenwald

Email: egreenwald@axinn.com

Karen Elizabeth Keller

Shaw Keller LLP

Tel: +1 (302) 298-0700

1105 North Market Street, 12th Floor, Wilmington, DE 19801

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 3 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials 1 proceeding
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (3): 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (1 found):
PTAB: 1
USPTO PTAB Trial 2016-06-11
IPR2016-01186

Merck Sharp & Dohmen Corp. v. Mayne Pharma International Pty Ltd.

Asserted Patent
Status: Final Written Decision
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Standard Essential Patent (SEP) & FRAND Intelligence

5G SEP • ETSI Declared High-Probability SEP Action

Essential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation

FRAND Encumbered
Essential Standard 4G / 5G LTE Generation: 5G
Standard Setting Org (SSO) ETSI / 3GPP Essential specification under ETSI / 3GPP governance
FRAND Commitment Committed Fair, Reasonable & Non-Discrim.
Known Patent Pools Avanci / Sisvel / Via Licensing Coverage Applicable Declarant: Sharp

Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)

Permanent Injunction Restricted

Asserted by recognized SEP declarant; CJEU Huawei v. ZTE restrictions apply.

✓ Patentee bound by SSO IPR Policy (ETSI Annex 6 / IEEE Patent Policy).
✓ Right to demand global FRAND portfolio determination.
✓ Non-discrimination defense: check licensing terms offered to competing implementers.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6881745
Pharmaceutical compositions for poorly soluble drugs
Filed: 2003-06-16
Issued: 2005-04-19
Expired (Term Ended)
Expires: 2023-06-16

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

63

Dispositive

13

Granted

0

Denied

0

Pending / Review

45

Motions by Category

Motion to Transfer Venue (28 U.S.C. § 1404) 2 Procedural / Extension Motion 20 Motion to Dismiss (FRCP 12(b)(6)) 5 Claim Construction / Markman Filing 29 Motion to Dismiss 1 Motion to Stay Pending IPR / Reexam 5 Motion to Stay 1

Key Dispositive Motions & Rulings

Motion to Stay Pending IPR / Reexam Moot / Terminated
SO ORDERED, re 137 Stipulated Order to Stay Pending Inter Partes Review -- Case Stayed. Motions withdrawn and terminated: 119 REQUEST for Certification of Direc...
Entry #— • 2017-02-09
Motion to Stay Pending IPR / Reexam Pending / Under Review
STIPULATION and (proposed) Order to Extend Time to respond to February 9, 2017 re 121 MOTION to Stay Pending Inter Partes Review, 119 REQUEST for Certification ...
Entry #136 • 2017-02-02 Document →
Motion to Stay Pending IPR / Reexam Pending / Under Review
MOTION to Stay Pending Inter Partes Review - filed by Merck & Co., Inc., Merck Sharp & Dohme Corp.. (Kraftschik, Stephen) (Entered: 01/19/2017)
Entry #121 • 2017-01-19 Document →
Motion to Stay Pending IPR / Reexam Pending / Under Review
[SEALED] OPENING BRIEF in Support re 121 MOTION to Stay Pending Inter Partes Review filed by Merck & Co., Inc., Merck Sharp & Dohme Corp..Answering Brief/Respon...
Entry #122 • 2017-01-19 Document →
Motion to Stay Pending IPR / Reexam Pending / Under Review
[SEALED] DECLARATION re 121 MOTION to Stay Pending Inter Partes Review, 119 REQUEST for Certification of Direct Appeal to the U.S. Court of Appeals - Defendants...
Entry #123 • 2017-01-19 Document →
Motion to Transfer Venue (28 U.S.C. § 1404) Referred to Magistrate
ORAL ORDER: IT IS HEREBY ORDERED that this case is no longer referred to Magistrate Judge Burke for matters related to scheduling. After entry of this order, if...
Entry #— • 2016-04-19

Docket Entries

(243 total)
Pleading / Complaint

COMPLAINT filed with Jury Demand against Merck & Co., Inc., Merck Sharp & Dohme Corp., N.V. Organon - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1730253.) - filed by Mayne Pharma International Pty Ltd.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(sar) (Entered: 05/29/2015)

Entry #1 • 2015-05-29
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (sar) (Entered: 05/29/2015)

Entry #2 • 2015-05-29
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,881,745 B2;. (sar) (Entered: 05/29/2015)

Entry #3 • 2015-05-29
1

Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Mayne Pharma International Pty Ltd.. (sar) (Entered: 05/29/2015)

Entry #4 • 2015-05-29
1

Summons Issued with Magistrate Consent Notice attached as to Merck & Co., Inc. on 5/29/2015; Merck Sharp & Dohme Corp. on 5/29/2015; N.V. Organon on 5/29/2015. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (sar)

Entry #5 • 2015-05-29
1
No Actions

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc